Table 1

Characteristics of the ustekinumab-treated cohort

CharacteristicsMedian (IQR) or n (%)
Total n=110
Sex: male65 (59)
Age at drug initiation, years40 (29–59)
Age at diagnosis, years30 (21–45)
Weight, kg75 (66–88)
Disease duration, years7 (3–13)
Disease extent, Montreal
 E1: Proctitis4 (4)
 E2: Left-sided colitis47 (43)
 E3: Extensive colitis59 (54)
Current smoker5 (5)
Prior immunomodulator
 Thiopurine60 (55)
 Methotrexate16 (15)
 Tacrolimus6 (5)
 ≥2 immunomodulators19 (17)
 None12 (11)
Prior biologic/small molecules
 Bio naïve4 (4)
 ≥1 anti-TNF agent71 (65); IFX 43, ADA 47,
GOL 2
 ≥2 anti-TNF agents21 (19)
 Vedolizumab59 (54)
 Tofacitinib35 (32)
 Anti-TNF + vedolizumab36 (33)
 Anti-TNF + vedolizumab + tofacitinib19 (17)
Corticosteroids at induction65 (59)
Immunosuppressant at induction13 (12)
Clinical and biochemical disease activity
 SCCAI (n=80)6 (4–7)
 Haemoglobin g/L (n=106)128.4±15.9
 Serum albumin, g/L (n=103)37.8±5.5
 CRP, mg/L (n=105)3 (1–9)
 Faecal calprotectin, µg/g (n=60)601 (325–984)
Baseline endoscopic assessment (n=67)
 UCEIS (n=55)*5 (4–5)
 Mayo endoscopic subscore (n=37)*2 (2–3)
Ustekinumab therapy
 Induction dose, n (%)260 mg, 7 (6), 390 mg, 76(69),
520 mg, 27(25)
 Total induction dose per kg5.4
  • *Method of endoscopic scoring varied per study site.

  • ADA, adalimumab; CRP, C reactive protein; GOL, golimumab; IFX, infliximab; IQR, interquartile range; SCCAI, Simple Clinical Colitis Activity Index ; TNF, tumour necrosis factor; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.